The merger effectively hands control to Slate with FULC shareholders retaining only a residual 5% stake plus a special dividend. The low ownership level combined with early-stage pipeline risk (SLTE-1009 still pre-Phase 1) suggests limited upside for current FULC holders. Monitor the shareholder vote and HSR clearance timeline - any deal disruption risk could further pressure FULC shares.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 17 $3.84entry
- T+1 · 3mo ago +0.78%α +1.46% · $3.87
- T+5 · 3mo ago 0.00%α +1.19% · $3.84
- T+20 · 2mo ago −1.56%α +0.42% · $3.78
- T+60 · 7d ago −3.13%α −0.18% · $3.72
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Fulcrum Therapeutics (FULC) filed a Rule 425 transcript of a joint conference call with Slate Medicines, confirming the all-stock merger announced August 16, 2026. The call reiterates the deal structure: Fulcrum stockholders will own ~5% of the combined company, Slate stockholders ~55.9%, PIPE investors ~39.1%, with a special cash dividend of excess cash above $20.3M to pre-merger Fulcrum holders. The deal transforms FULC into a migraine-focused biotech under Slate management (ticker expected to become SLTE), funded by a $245M PIPE providing cash runway into 2029.
Key Financial Metrics
Key Facts
- Pre-merger Fulcrum stockholders to own ~5% of the combined company on a fully-diluted basis (down from 100% control).
- Pre-merger Slate stockholders to own ~55.9%, PIPE investors ~39.1%.
- Fulcrum to contribute net cash of $20.3M at close, with excess cash (~$270M) paid as a special dividend to pre-merger Fulcrum holders.
- $245M concurrent private placement led by Frazier Life Sciences with participation from Forbion, RA Capital, Deep Track, Foresite, OrbiMed, RTW, Mingxin.
- Combined company expected to be renamed Slate Medicines, Inc. and trade as SLTE on Nasdaq.
- Slate lead candidate SLTE-1009 (anti-PACAP/VIP mAb) Phase 1 data expected mid-2027, Phase 2 in H2 2027.
- Second program SLTE-2100 (bispecific PACAP/VIP+CGRP) expected to enter clinic H2 2027.
- Cash runway expected into 2029; deal expected to close Q4 2026 subject to stockholder approval and HSR clearance.
Financial Impact
Fulcrum shareholders are diluted from 100% to ~5% ownership; ~$270M excess cash returned as special dividend. No standalone revenue or EPS for the combined entity provided in this filing.
Risk Factors
- Shareholder vote required - large institutional holders may oppose the 5% residual stake.
- HSR antitrust clearance required.
- Clinical risk: SLTE-1009 and SLTE-2100 are early-stage (preclinical/Phase 1) with no human efficacy data.
- Combined company has no approved products; reliance on $245M PIPE for runway into 2029.
- Ticker change to SLTE may trigger index/ETF selling of FULC positions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001193125-26-353282 |
| Document: 0001193125-26-353282-index-headers.html | 0001193125-26-353282 |
| Document: 0001193125-26-353282-index.html | 0001193125-26-353282 |
| Document: 0001193125-26-353282.txt | 0001193125-26-353282 |
Track record
23 reports on FULC
6 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +7.71% at T+60 after the Jul 15, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $3.72 Now $3.71 −0.27% settles Nov 18
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.73 Now $3.71 −0.40% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 12, 20264d ago 425 Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 5, 202612d ago EFFECT Neutral 4/10 Entry $3.68 to $3.70 Now $3.71 +0.82% ▲ +0.54% +0.23% vs SPY
- Nov 3, 202613d ago S-4/A Neutral 5/10 Entry $3.74 to $3.77 Now $3.71 −0.80% ▲ +0.80% −0.85% vs SPY
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers